Careers  |  Sign In  |  Register  |   Twitter

Latest in Hematology-Oncology

Craig A. Dionne, PhD, CEO of GenSpera, describes some of the drawbacks associated with common cancer treatments. Many types of drug therapies, like antiangiogenics and immunotherapies, may only be effective in 15-30% of patients. Chemotherapy can be effective in a greater percentage of patients, but causes...
The Fn14 molecule found on tumors may be a major cause of emaciation in cancer sufferers.
Mipsagargin (G-202), a new prodrug developed by GenSpera, has a unique mechanism of action that allows it to kill cancer cells without damaging surrounding tissues. Derived from thapsigargin, the powerful toxin present in the Thapsia garganica plant, mipsagargin can combat any tumor with PSMA enzyme...